Background: Anal cancer is a relatively common cancer among HIV-infected populations. There are limited data on the prevalence of anal high-risk human papillomavirus (HR-HPV) infection and anal dysplasia in HIV-infected women from resourceconstrained settings.
INTRODUCTION
As HIV-infected patients live longer because of effective combination antiretroviral therapy (cART), an increased risk for non-AIDS-defining cancers is being reported. 1 HIVinfected individuals are at increased risk of virally mediated cancers. 1, 2 Anal cancer, which is caused by high-risk types of human papillomavirus (HR-HPV), is a relatively common cancer among men who have sex with men and HIV-infected men and women. [3] [4] [5] The rates of anal cancer have risen significantly in HIV-infected women from very low rates during 1980-1989 to 11/100,000 person-years during 1996-2004. 6 A systematic review found that the anal cancer incidence among HIV-infected women ranged from 3.9 to 30/100,000 person-years and the standardized incidence rate ranged from 3.2 to 41.2 compared with the general population. 7 Sub-Saharan Africa has the largest population of HIVinfected people and over 50% are women. 8 Although cervical cancer rates have declined to ,10/100,000 person-years in the USA, the rates in sub-Saharan Africa are 30-40/100,000 person-years in the general population 9 and are 3-5 times higher among HIV-infected women. 10, 11 The prevalence of cervical HR-HPV infection is high among HIV-infected women from sub-Saharan Africa, and multiple HR-HPV infections are often detected. 12, 13 Cervical HR-HPV infection and dysplasia have been shown to be correlated with anal HR-HPV infection and dysplasia. 14, 15 There is a 2-4-fold increase risk of anal high-grade squamous intraepithelial lesions (HSIL) among HIV-infected women who have a history of cervical dysplasia. 5, 16, 17 In sub-Saharan Africa, there are no data on the prevalence of anal HR-HPV infection and anal HSIL among HIV-infected women. Moreover, the rates of anal cancer have not been well described. We present data on anal HR-HPV infection and anal dysplasia in HIV-infected women recruited from an HIV treatment clinic located in Johannesburg, South Africa.
METHODS

Study Design
HIV-infected women aged 25-65 years were recruited from Themba Lethu Clinic (TLC), the HIV unit at Helen Joseph Hospital, Johannesburg, South Africa. Women were educated regarding the study and then signed informed consent. The inclusion criteria were documented HIV infection, age 25-65, and ability to give consent and participate in study-related activities. Exclusion criteria were pregnancy, clinically active sexually transmitted infection (participation was allowed after the sexually transmitted infection treatment was completed), previous hysterectomy with removal of the cervix, and significant medical/mental illness that would prevent the participant from completing the study. Participants completed a counselor-administered questionnaire on demographics, sexual history, and medical history specific to cervical and anal dysplasia. Participants underwent 3 anal swabs (1 for conventional cytology and 2 for HR-HPV testing), and vaginal speculum examination for cytobroom collection for conventional cervical cytology and 2 cervical swabs for HR-HPV testing. Individual cervical and anal swabs were placed into vials of Digene Specimen Transport Medium and PreservCyt. We used conventional cytology as liquid-based cytology was not available within the South African public health sector at the time of this trial. Participants with an abnormal anal cytology defined as atypical squamous cells (ASC) or greater, and 20% of those with a negative cytology were asked to return for highresolution anoscopy (HRA) with biopsy of visible lesions. HRA was performed as described previously. 18 Anoscopists were experienced cervical colposcopy providers and were trained in HRA by an experienced anoscopist. Ongoing quality assurance activities included quarterly reviews of digital HRA photographs and periodic in-person observation and mentoring of HRA procedures. HR-HPV testing was performed using Digene Hybrid Capture 2 (Qiagen Inc., Gaithersburg, MD) on the Digene Specimen Transport Medium and Aptima HPV E6/E7 messenger RNA (mRNA) assay (Hologic Inc., San Diego, CA) on a 1-mL aliquot of PreservCyt. These HR-HPV tests are not approved by the U. S. Food and Drug Administration for anal testing.
Pathology
Cervical and anal cytology was reported using the Bethesda system and were classified as negative, atypical squamous cells of uncertain significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), HSIL and ASCUS where a high-grade lesion could not be excluded (ASC-H), and squamous-cell carcinoma. 19 A single pathologist (P.M.) interpreted all the anal and cervical cytology results. HRA histology results were classified as normal, LSIL, and HSIL. Condyloma and atypia were considered LSIL for the purposes of analysis. Immunohistochemistry staining for p16 was not performed routinely for anal intraepithelial neoplasia grade 2 as recommended by the Lower Anogenital Screening Terminology Standardization Project. 20 The pathologists were not masked to the cytology results but were masked to the HR-HPV results. Histology specimens were interpreted by multiple pathologists from the South African National Health Laboratory Service in Johannesburg.
Statistical Analysis
Baseline characteristics of this cohort and the prevalence of anal SIL were summarized using descriptive statistics. If multiple anal biopsies were obtained, the most severe result was taken as the final diagnosis. Participants with inadequate biopsies taken or were lost to follow-up were removed from histology analyses. Student t test was used to compare log-transformed Hybrid Capture 2 relative light units. Logistic regression was used to evaluate the relationship of various factors to the presence of anal HR-HPV DNA, anal E6/E7 mRNA, and anal HSIL (defined as HSIL on cytology or histology or ASC-H on cytology). A single multivariable model was constructed for all 3 outcomes using all factors significant in one or more univariable models. All statistical analysis was performed using SAS version 9.4 (Cary, NC).
RESULTS
Two hundred women were enrolled. Baseline characteristics of participants are described in Tables 2 and 3 show the cytological results according to HR-HPV status.
The HRA disposition is shown in Figure 1 . One hundred forty-eight women with abnormal anal cytology were referred for HRA. Results are available on 140/148 (95%) women (4 did not return for HRA and 4 had biopsies obtained that did not yield a result). Seventeen women were diagnosed with anal HSIL on histology. Of the 51/199 (26%) women with normal anal cytology, 10 were referred for HRA and results are available for 9 women; 1 did not return for HRA. No woman with normal anal cytology was diagnosed with HSIL. LSIL or atypia was found on anal histology in 72 of 149 (48%) women with HRA results.
Thirty-one participants had anal HSIL (defined as HSIL detected by anal histology or cytology or ASC-H on anal cytology). Anal HR-HPV DNA detection had the following test characteristics for HSIL: sensitivity 77% (95% CI: 59% to 90%), specificity 65% (95% CI: 58% to 73%), and positive predictive value 29% (20%-40%). E6/E7 mRNA had a sensitivity of 50% (95% CI: 29% to 71%), specificity of 89% (95% CI: 83% to 93%), and positive predictive value of 40% (95% CI: 23% to 59%).
We evaluated factors associated with anal HR-HPV DNA detection, HPV E6/E7 mRNA detection, and anal HSIL (Table 4) . Anal HR-HPV DNA was independently associated with younger age, and anal condyloma with a statistically nonsignificant association for lower current CD4 counts, and 
DISCUSSION
These are the first data on the prevalence of anal HR-HPV infection and SIL among HIV-infected women in subSaharan Africa. We found a high prevalence of these conditions, which is expected given the high rates of cervical HR-HPV, dysplasia, and cancer that have been reported in this population. Biological similarities between anal and cervical cancer include HR-HPV infection as the etiologic agent and detectable HSIL as the precursor lesion to cancer. HPV types 16 and 18 have been isolated in approximately 70% of cervical and 80% of anal cancers. 21, 22 Studies have shown a strong association between HIV infection and anal HR-HPV prevalence in both men and women. 23, 24 Our study found a similar prevalence of anal and cervical HR-HPV infection, which is consistent with previous studies. 16, 25 Our estimate of anal HSIL is similar to previous studies of HIV infected from the USA, France, and Brazil. 5, 7, 16, 25 However, ours is likely an underestimate. Studies using expert HRA providers have found a higher prevalence of HSIL. A previous study in U.S. HIV-infected men who had sex with men found that 38% of those having abnormal cytology had HSIL detected on anal histology, 26 whereas we found that 17 of 140 women with abnormal cytology (12%) who underwent HRA had anal HSIL detected by histology. Baseline analyses of a cohort of HIV-infected women found that 72/225 (28%) had anal HSIL, including 16% of women with normal anal cytology, 29% of women with ASCUS/ LSIL cytology, and 72% of women with HSIL/ASC-H. 27 In comparison, we found HSIL in no women with normal anal cytology, 9% of women with ASCUS/LSIL cytology and 33% of women with HSIL/ASC-H ( Table 5 ). The prevalence of anal HR-HPV was similar in these studies 48% and 43%, respectively. The prevalence of anal and cervical HR-HPV infection was lower in those with longer duration of cART use. This relationship was seen for cervical HR-HPV infection in the Women's Interagency HIV Study. 28 The interplay between HIV and HR-HPV infection is complex and not well understood. In our cohort, we did not see a relationship between CD4 count and anal HSIL. This could be due to the possible ascertainment bias of HSIL, the relatively small sample size, or the relative high median CD4 count [430 (IQR: 311-600) cells/mm 3 ]. The Strategic Timing of Antiretroviral Therapy (START) study, which randomized cARTnaive, HIV-infected participants with CD4 over 500 cells/ mm 3 to immediate or deferred cART, found a 63% reduction in virally mediated cancers. 29 Hopefully, earlier initiation of cART, as recommended by the World Health Organization, 30 will result in a lower incidence of HPV-associated cancer.
The E6/E7 mRNA assay had lower sensitivity (50% vs. 77%) and a higher specificity for anal HSIL than did HR-HPV DNA (89% vs. 65%). Other studies have found that the sensitivity of E6/E7 mRNA for cervical HSIL was similar to HR-HPV DNA assays. 31, 32 It is not clear why the sensitivity of E6/E7 mRNA for anal HSIL appeared lower in our study. Our estimated sensitivity was similar when considering HSIL on histology alone, HSIL on cytology, or HSIL on either test (data not shown). It is possible that the swab order may have been a factor. The swab placed into PreservCyt was the third swab obtained, after cytology and HR-HPV DNA, and this may have resulted in less cellular material available for analysis. It is important to note that 15/199 (8%) did not have a valid result suggesting issues with the specimen quality. Additional studies are needed to clarify the utility of HPV mRNA assays for anal cancer screening.
We were unable to evaluate the role of receptive anal sex in this population, as we asked about anal sex in the previous 6 months rather than lifetime history using an interviewer-administered questionnaire. Querying about lifetime history and use of computer-assisted structured interviewing would have been a preferred approach. Although receptive anal sex has been shown to be a risk factor for anal HSIL, anal HSIL is commonly found among HIV-infected women who do not report that history. 33 In addition to limitations discussed above, HPV typing would have allowed for more detailed analyses of anal and cervical HR-HPV infections to elucidate the relationship between these infections. This study was a cross-sectional assessment. Longitudinal follow-up would have allowed additional opportunities for the diagnosis of anal HSIL. Although we did not identify anal HSIL among women with normal anal cytology, a more robust assessment of anal HSIL prevalence would have been possible if all women had undergone HRA.
We found a high prevalence of anal infection with HR-HPV and anal dysplasia among HIV-infected women in Johannesburg, South Africa. Further studies are needed to define the incidence of anal cancer in this population. Prospective cohort studies to better understand the epidemiology of anal HSIL in this population should be considered. These data are needed before anal cancer screening can be considered in this region. 
